Breaking FCC Chairman Defends Agency Actions Amidst ABC Dispute Big Ten Conference Counters ‘Top-Heavy’ Narrative with Championship Claims Migrant Influx Swells Spanish Enclave to Near-Capacity Travis Hunter Eyes Stronger Return to Jaguars Training Camp After Injury Regulators Propose Major Overhaul to Community Reinvestment Act

Friday July 31, 2026

Reporter

Johnson & Johnson

2Articles Published

5Communities Covered

Published Articles

Press Release

Johnson & Johnson’s RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Jul 30

Press Release

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Jul 23